Abstract:Background Alternative splicing (AS) is a gene regulatory mechanism that drives protein diversity. Dysregulation of AS is thought to play an essential role in cancer initiation and development. This study aimed to construct a prognostic signature based on AS and explore the role in the tumor immune microenvironment (TIME) in lung adenocarcinoma. Methods We analyzed transcriptome profiling and clinical lung adenocarcinoma data from The Cancer Genome Atlas (TCGA) database and lists of AS-related and immune-related signatures from the SpliceSeq. Prognosis-related AS events were analyzed by univariate Cox regression analysis. Gene set enrichment analyses (GSEA) were performed for functional annotation. Prognostic signatures were identified and validated using univariate and multivariate Cox regression, LASSO regression, Kaplan–Meier survival analyses, and proportional hazards model. The context of TIME in lung adenocarcinoma was also analyzed. Gene and protein expression data of Cyclin-Dependent Kinase Inhibitor 2A (CDKN2A) were obtained from ONCOMINE and Human Protein Atlas. Splicing factor (SF) regulatory networks were visualized. Results A total of 19,054 survival-related AS events in lung adenocarcinoma were screened in 1,323 genes. Exon skip (ES) and mutually exclusive exons (ME) exhibited the most and fewest AS events, respectively. Based on AS subtypes, eight AS prognostic signatures were constructed. Patients with high-risk scores were associated with poor overall survival. A nomogram with good validity in prognostic prediction was generated. AUCs of risk scores at 1, 2, and 3 years were 0.775, 0.736, and 0.759, respectively. Furthermore, the prognostic signatures were significantly correlated with TIME diversity and immune checkpoint inhibitor (ICI)-related genes. Low-risk patients had a higher StromalScore, ImmuneScore, and ESTIMATEScore. AS-based risk score signature was positively associated with CD8+ T cells. CDKN2A was also found to be a prognostic factor in lung adenocarcinoma. Finally, potential functions of SFs were determined by regulatory networks. Conclusion Taken together, our findings show a clear association between AS and immune cell infiltration events and patient outcome, which could provide a basis for the identification of novel markers and therapeutic targets for lung adenocarcinoma. SF networks provide information of regulatory mechanisms.

Systematic Analysis of Survival-Associated Alternative Splicing Signatures in Gastrointestinal Pan-Adenocarcinomas

Survival-associated alternative splicing events interact with the immune microenvironment in stomach adenocarcinoma

Systematic Analysis of Alternative Splicing Landscape in Pancreatic Adenocarcinoma Reveals Regulatory Network Associated with Tumorigenesis and Immune Response

Features of Alternative Splicing in Stomach Adenocarcinoma and Their Clinical Implication: a Research Based on Massive Sequencing Data

Survival-associated alternative splicing signatures in esophageal carcinoma

Signature of gene aberrant alternative splicing events in pancreatic adenocarcinoma prognosis

Characterization of alternative splicing events and prognostic signatures in gastric cancer

Screening Gene Expression-Related Alternative Splicing Event Signature for Colon Cancer Prognostic Prediction

Systematic Analysis of Survival‐associated Alternative Splicing Signatures in Clear Cell Renal Cell Carcinoma

Genome-Wide Profiling of Alternative Splicing Signature Reveals Prognostic Predictor for Esophageal Carcinoma

Systematic Profiling of Alternative Splicing Signature Reveals Prognostic Predictor for Prostate Cancer

Determining the prognostic significance of alternative splicing events in soft tissue sarcoma using data from The Cancer Genome Atlas

Comprehensive Analysis of Prognostic Alternative Splicing Signatures in Oral Squamous Cell Carcinoma

Landscape analysis of alternative splicing in kidney renal clear cell carcinoma and their clinical significance

Systemic Analysis of RNA Alternative Splicing Signals Related to the Prognosis for Head and Neck Squamous Cell Carcinoma

Prognostic Alternative Mrna Splicing Signature in Hepatocellular Carcinoma: a Study Based on Large-Scale Sequencing Data

Prognostic Alternative Splicing Regulatory Network of Splicing Events in Acute Myeloid Leukemia Patients Based on SpliceSeq Data from 136 Cases

Alternative splicing acts as an independent prognosticator in ovarian carcinoma

A Prediction Model Using Alternative Splicing Events and the Immune Microenvironment Signature in Lung Adenocarcinoma

Landscape of Alternative Splicing Events Related to Prognosis and Immune Infiltration in Glioma: A Data Analysis and Basic Verification

Genome-wide identification of pan-cancer common and cancer-specific alternative splicing events in 9 types of cancer